Poolbeg Pharma PLC (LON:POLB – Get Free Report) hit a new 52-week low on Wednesday . The company traded as low as GBX 3 ($0.04) and last traded at GBX 3.01 ($0.04), with a volume of 869168 shares changing hands. The stock had previously closed at GBX 3.24 ($0.04).
Analysts Set New Price Targets
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
Get Our Latest Stock Report on Poolbeg Pharma
Poolbeg Pharma Trading Down 7.1 %
About Poolbeg Pharma
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
Featured Articles
- Five stocks we like better than Poolbeg Pharma
- Investing In Preferred Stock vs. Common Stock
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Health Care Stocks Explained: Why You Might Want to Invest
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
